Advertisements



GlaxoSmithKline And Merck KGaA Position For The Next Wave In Immuno-Oncology

GlaxoSmithKline And Merck KGaA Position For The Next Wave In Immuno-Oncology.....»»

Category: topSource: seekingalphaFeb 11th, 2019

Merck KGaA agrees $6.5 billion takeover of Versum

Germany's Merck KGaA said it signed a takeover agreement with target Versum Materials for a price of $53 per share after Versum walked away from a prior merger agreement with rival Entegris......»»

Category: topSource: reutersApr 12th, 2019

Merck KGaA in definitive agreement to acquire Versum in deal with enterprise value of 5.8 bln euros

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchApr 12th, 2019

Merck KGaA expects deal to immediately boost earnings per share

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchApr 12th, 2019

Merck KGaA expects deal to close in second half

This is a Real-time headline. These are breaking news, delivered the minute it happens, delivered ticker-tape style. Visit www.marketwatch.com or the quote page for more information about this breaking news......»»

Category: topSource: marketwatchApr 12th, 2019

Versum Materials Says Revised Merck KGaA Buyout Proposal "Superior" To Entegris Offer

Versum Materials, Inc. (NYSE: VSM) announced Monday that it received a revised proposal from Merck KGaA to acquire Versum for $53 per share, up from Merck's prior $48-per-share proposal on Feb. 27.  read more.....»»

Category: blogSource: benzingaApr 8th, 2019

Versum Materials Says Revised Merck Buyout Proposal "Superior" To Entegris Offer

Versum Materials, Inc. (NYSE: VSM) announced Monday that it received a revised proposal from Merck KGaA to acquire Versum for $53 per share, up from Merck's prior $48-per-share proposal on Feb. 27.  read more.....»»

Category: blogSource: benzingaApr 8th, 2019

Versum says revised proposal from Merck KGaA "superior" to Entegris

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 8th, 2019

Merck KGaA wins Versum"s support for sweetened $6.5 billion offer

Merck KGaA won the support of Versum Materials Inc's board with a sweetened $6.5 billion takeover proposal, topping an agreed merger with rival Entegris......»»

Category: topSource: reutersApr 8th, 2019

Veeva says Healthcare business of Merck KGaA selects Veeva CRM

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 4th, 2019

Merus Announces Financial Results for the Full Year 2018 and Provides Business Update

UTRECHT, The Netherlands, April 03, 2019 (GLOBE NEWSWIRE) -- Merus N.V. (NASDAQ:MRUS) ("Merus", "we", "our" or the "Company"), a clinical-stage immuno-oncology company developing Biclonics®, innovative full-length hum.....»»

Category: earningsSource: benzingaApr 3rd, 2019

Nektar presents data on its immuno-oncology pipeline candidates

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 2nd, 2019

Trillium expands immuno-oncology pipeline with STING agonist program

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 2nd, 2019

Inovio completes enrollment of Phase 1/2 immuno-oncology trial ahead of schedule

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallApr 1st, 2019

Versum opens books, begins to warm to rival suitor Merck KGaA

Versum Materials Inc has opened its books to suitor Merck KGaA, saying the German group's unsolicited $5.9 billion offer might be sweetened and could edge out an agreed merger with Entegris......»»

Category: topSource: reutersMar 29th, 2019

Versum Materials" board rejects unsolicited tender offer from Merck KGaA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 29th, 2019

OSE Immunotherapeutics Reports 2018 Financial Results and Business Update

Four differentiated therapeutic programs progressing through clinical studies in immuno-oncology and autoimmune diseases OSE's partnership business model based on innovative products; Multiple validating partnering milestones generated €35 milli.....»»

Category: earningsSource: benzingaMar 28th, 2019

Versum Materials confirms $48 per share offer from Merck KGaA

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 26th, 2019

Merck KGaA goes hostile in $5.9 billion Versum takeover battle

German pharma group Merck KGaA on Tuesday sidestepped the management of takeover target Versum Materials and took its $5.9 billion offer directly to the U.S. chemical company's shareholders......»»

Category: topSource: reutersMar 26th, 2019

Merck KGaA takes $48/share Versum offer to shareholders, Reuters reports

See the rest of the story here. Theflyonthewall.com provides the latest financial news as it breaks. Known as a leader in market intelligence, The Fl.....»»

Category: blogSource: theflyonthewallMar 26th, 2019

Biotech Analysis Central Pharma News: AbbVie"s Trouble, Merck KGaA"s Bad Streak, Puma"s Positive Data

Biotech Analysis Central Pharma News: AbbVie"s Trouble, Merck KGaA"s Bad Streak, Puma"s Positive Data.....»»

Category: topSource: seekingalphaMar 20th, 2019